Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.

Enzyme replacement therapy (ERT) is the standard-of-care treatment of Pompe disease, a lysosomal storage disorder caused by deficiency of acid α-glucosidase (GAA). One limitation of ERT with recombinant human (rh) GAA is antibody formation against GAA. Similarly, in adeno-associated virus (AAV) vector-mediated gene transfer for Pompe disease, development of antibodies against the GAA transgene product and the AAV vector prevents therapeutic efficacy and vector readministration, respectively. Here a nondepleting anti-CD4 monoclonal antibody (mAb) was administrated intravenously prior to administration of an AAV2/9 vector encoding GAA to suppress anti-GAA responses, leading to a substantial reduction of anti-GAA immunoglobulins, including IgG1, IgG2a, IgG2b, IgG2c, and IgG3. Transduction efficiency in liver with a subsequent AAV2/8 vector was massively improved by the administration of anti-CD4 mAb with the initial AAV2/9 vector, indicating a spread of benefit derived from control of the immune response to the first AAV2/9 vector. Anti-CD4 mAb along with AAV2/9-CBhGAApA significantly increased GAA activity in heart and skeletal muscles along with a significant reduction of glycogen accumulation. Taken together, these data demonstrated that the addition of nondepleting anti-CD4 mAb with gene therapy controls humoral immune responses to both vector and transgene, resulting in clear therapeutic benefit in mice with Pompe disease.

[1]  H. Waldmann,et al.  Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease , 2014, Molecular genetics and metabolism reports.

[2]  Songtao Li,et al.  Assessment of toxicity and biodistribution of recombinant AAV8 vector–mediated immunomodulatory gene therapy in mice with Pompe disease , 2014, Molecular therapy. Methods & clinical development.

[3]  J. Charrow,et al.  Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT , 2013, PloS one.

[4]  Nina Raben,et al.  Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease , 2013, EMBO molecular medicine.

[5]  T. Weber,et al.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. , 2013, Human gene therapy methods.

[6]  D. Lockhart,et al.  The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease , 2012, PloS one.

[7]  Songtao Li,et al.  Deficiency in MyD88 Signaling Results in Decreased Antibody Responses to an Adeno-Associated Virus Vector in Murine Pompe Disease , 2012, BioResearch open access.

[8]  C. Dunbar,et al.  Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  J. Charrow,et al.  Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. , 2012, Molecular genetics and metabolism.

[10]  A. Kemper,et al.  Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia. , 2012, Human gene therapy.

[11]  R. Rodriguiz,et al.  Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. , 2012, Human gene therapy.

[12]  D. Dimmock,et al.  Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease , 2012, Genetics in Medicine.

[13]  A. Kemper,et al.  Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Z. Illés,et al.  Enzyme replacement therapy induces T‐cell responses in late‐onset Pompe disease , 2011, Muscle & nerve.

[15]  Yuan-Tsong Chen,et al.  The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease , 2011, Genetics in Medicine.

[16]  A. Davidoff,et al.  Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine , 2011, Gene Therapy.

[17]  Lili Wang,et al.  Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. , 2011, Human gene therapy.

[18]  M. Kroos,et al.  High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. , 2010, Molecular genetics and metabolism.

[19]  M. Komatsu,et al.  Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder—murine Pompe disease , 2010, Autophagy.

[20]  A. Kemper,et al.  Antibody formation and mannose‐6‐phosphate receptor expression impact the efficacy of muscle‐specific transgene expression in murine Pompe disease , 2010, The journal of gene medicine.

[21]  J. Ravetch,et al.  FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo , 2010, Proceedings of the National Academy of Sciences.

[22]  T. Conlon,et al.  Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia. , 2010, Human gene therapy.

[23]  C. Leborgne,et al.  Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. , 2010, Human gene therapy.

[24]  M. Kulis,et al.  Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Y. Chien,et al.  Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment , 2009, Pediatrics.

[26]  R. Auten,et al.  Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  T. Taksir,et al.  Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. , 2008, Human gene therapy.

[28]  D. Koeberl,et al.  Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. , 2007, American journal of human genetics.

[29]  R. Herzog,et al.  Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. , 2007, Blood.

[30]  R. Herzog,et al.  Muscle as a target for supplementary factor IX gene transfer. , 2007, Human gene therapy.

[31]  N. Raben,et al.  Role of autophagy in the pathogenesis of Pompe disease. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[32]  Z. Xiang,et al.  Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  B. Byrne,et al.  Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  L. Couto,et al.  Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. , 2006, Blood.

[35]  J. Sommer,et al.  Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. , 2006, Blood.

[36]  D. Koeberl,et al.  Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  R. Herzog,et al.  Major role of local immune responses in antibody formation to factor IX in AAV gene transfer , 2005, Gene Therapy.

[38]  M. Karim,et al.  CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. , 2005, Blood.

[39]  D. Koeberl,et al.  Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  Lili Wang,et al.  Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. , 2005, Blood.

[41]  B. Byrne,et al.  Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II. , 2005, Human gene therapy.

[42]  A. Amalfitano,et al.  Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model , 2004, Gene Therapy.

[43]  R. Bräuer,et al.  Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation , 2004, Annals of the rheumatic diseases.

[44]  H. Waldmann,et al.  Induction of Immunological Tolerance/Hyporesponsiveness in Baboons with a Nondepleting CD4 Antibody , 2004, The Journal of Immunology.

[45]  R. Samulski,et al.  Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo , 2003, Gene Therapy.

[46]  N. Raben,et al.  Enzyme replacement therapy in the mouse model of Pompe disease. , 2003, Molecular genetics and metabolism.

[47]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Byrne,et al.  Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  Yuan-Tsong Chen,et al.  Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  N. Raben,et al.  Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Russell,et al.  Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration , 1997, Journal of virology.

[52]  S. Cobbold,et al.  Mechanisms in CD4 antibody‐mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells , 1994, European journal of immunology.

[53]  A. Cooke,et al.  Prevention of diabetes but not insulitis in NOD mice injected with antibody to CD4. , 1993, Journal of autoimmunity.

[54]  H. Waldmann,et al.  Induction of classical transplantation tolerance in the adult , 1989, The Journal of experimental medicine.

[55]  H. Waldmann,et al.  Induction of tolerance by monoclonal antibody therapy , 1986, Nature.

[56]  T. Kovacevic,et al.  Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study , 2013, Wiener klinische Wochenschrift.

[57]  J. Markić,et al.  Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report. , 2012, JIMD reports.

[58]  H. Mandel,et al.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. , 2010, Molecular genetics and metabolism.

[59]  D. Koeberl,et al.  Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  J. Charrow,et al.  Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial , 2001, Genetics in Medicine.